Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Pronged attack shrink Hard-to-Treat cancers?

NCT ID NCT06022757

Terminated Disease control Sponsor: Evopoint Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study includes several cancer types, such as head and neck, lung, prostate, and bladder cancers. Researchers aim to find the best dose and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental EZH2 inhibitor called XNW5004 combined with the immunotherapy drug pembrolizumab (Keytruda)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply broadly. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma cervical cancer cervical squamous cell carcinoma head and neck squamous cell carcinoma metastatic prostate carcinoma neoplasm non-small cell lung carcinoma prostate cancer small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA CERVICAL CANCER NON-SMALL CELL LUNG CANCER OTHER SOLID TUMORS PROSTATE CANCER SMALL CELL LUNG CANCER SQUAMOUS CELL CARCINOMA OF HEAD AND NECK UROTHELIAL CARCINOMA

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center (SYSUCC)

    Guangzhou, Guodong Province, 528404, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.